Neurocrine Biosciences | Passivo Circulante



Current Liabilities Alterar Data
AbbVie USD 36.4B 2.35B 2025-03
Acadia Pharmaceuticals USD 330.02M 27.49M 2025-06
Agios Pharmaceuticals USD 70.41M 18.04M 2025-06
ALKERMES USD 505.96M 62.23M 2025-06
Alnylam Pharmaceuticals USD 1.3B 225.22M 2025-06
Amgen USD 20.48B 2.53B 2025-06
Biogen USD 3.18B 2.11B 2025-06
BioMarin Pharmaceutical USD 684.25M 56.03M 2025-06
Cytokinetics USD 131.06M 28.66M 2025-06
Dynavax Technologies USD 118.23M 49.85M 2025-06
Exelixis USD 336.11M 62.99M 2025-07
Gilead Sciences USD 11.19B 1.15B 2025-06
Halozyme Therapeutics USD 134.28M 16.1M 2025-06
Incyte USD 1.28B 608.18M 2025-06
Ionis Pharmaceuticals USD 897.24M 646.94M 2025-06
Neurocrine Biosciences USD 546.3M 23.4M 2025-06
Pfizer USD 37.73B 1.27B 2025-06
Prothena USD 48.5M 2.08M 2024-12
Regeneron Pharmaceuticals USD 3.67B 100.4M 2025-06
Repligen USD 152M 25.21M 2025-03
Sarepta Therapeutics USD 919.95M 314.36M 2025-06
Teva Pharmaceutical Industries USD 11.86B 704M 2025-06
Ultragenyx Pharmaceutical USD 293.24M 1.58M 2025-06
Vertex Pharmaceuticals USD 4.14B 355.2M 2025-06


Neurocrine Biosciences Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Aug 2025.